Parkinson’s UK and Domainex are teaming up to develop small molecules aimed at lessening chronic brain inflammation and slowing the progression of Parkinson’s disease. “We are thrilled to have been selected by Parkinson’s UK to work on this promising project which has the potential to improve the…
A National Institutes of Health (NIH) grant worth $3.2 million will further research into how the rewiring of serotonin-producing nerve cells — a chemical messenger mostly involved in mood, cognition and memory — might help with controlling movement in people with advanced Parkinson’s disease. The grant, given to Christopher…
Delve Health and Global Kinetics, two digital healthcare companies, are teaming up to simplify the remote monitoring, data collection and analysis of Parkinson’s disease patients enrolled in clinical studies. “This partnership represents both companies’ commitment to providing Parkinson’s patients quality solutions that are user-friendly within the context of…
People with Parkinson’s disease who regularly eat foods rich in flavonoids — plant-produced metabolites abundant in colorful fruits and plants, from berries and teas to dark chocolate and red wine — have a lower mortality risk than patients who rarely eat these foods, a study that followed people for up to…
South Carolina’s Integrated Micro-Chromatography Systems (IMCS) has been awarded a $1.8-million grant to advance the development of affordable gangliosides — fat molecules with a sugar link — to aid in developing therapeutics and diagnostics for Parkinson’s and other neurological diseases. The funds are part of a second parcel of…
Regular and sustained physical activity, including daily pursuits such as walking or gardening, may help slow the progression of Parkinson’s in people with early-stage disease, a long-term follow-up study suggests. Patients who exercised regularly over five years showed better motor and cognitive outcomes. “Our results are exciting, because they suggest it…
Zhittya Genesis Medicine plans to launch what it is calling a “Compassionate Use Clinical Trial” of FGF-1, a biological compound aiming to stimulate new blood vessel growth in the brain, for people with mild-to-moderately severe Parkinson’s disease. Those interested in joining this open-label (no placebo group) pilot safety and early efficacy…
People who took part in remote, video-conducted clinical trials for Parkinson’s disease reported high levels of satisfaction and interest in participating in future studies with remote video visits, scientists report. Three such trials showed that recruitment was feasible and enrolled participants were geographically dispersed — from across dozens of…
Biogen and Denali Therapeutics are planning to launch two late-stage clinical trials to further evaluate the potential of their investigational oral therapy BIIB122/DNL151 in treating people with Parkinson’s disease. The Phase 3 and Phase 2b trials, expected to commence this year, will be led by Biogen and follow promising results…
Oral health affects life quality in adults with Parkinson’s, with oral health worsening with disease progression and resulting in a related greater decline in quality of life than is evident in adults of similar age without this disorder, a small study from the Netherlands reports. Motor difficulties impacting daily…
Get regular updates to your inbox.